• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调节性 T 细胞整合天然和 CAR 介导的共刺激信号,以控制移植物排斥反应。

Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection.

机构信息

BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.

School of Biomedical Engineering and.

出版信息

JCI Insight. 2023 Oct 9;8(19):e167215. doi: 10.1172/jci.insight.167215.

DOI:10.1172/jci.insight.167215
PMID:37669115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10619441/
Abstract

Tregs expressing chimeric antigen receptors (CAR-Tregs) are a promising tool to promote transplant tolerance. The relationship between CAR structure and Treg function was studied in xenogeneic, immunodeficient mice, revealing advantages of CD28-encoding CARs. However, these models could underrepresent interactions between CAR-Tregs, antigen-presenting cells (APCs), and donor-specific Abs. We generated Tregs expressing HLA-A2-specific CARs with different costimulatory domains and compared their function in vitro and in vivo using an immunocompetent model of transplantation. In vitro, the CD28-encoding CAR had superior antigen-specific suppression, proliferation, and cytokine production. In contrast, in vivo, Tregs expressing CARs encoding CD28, ICOS, programmed cell death 1, and GITR, but not 4-1BB or OX40, all extended skin allograft survival. To reconcile in vitro and in vivo data, we analyzed effects of a CAR encoding CD3ζ but no costimulatory domain. These data revealed that exogenous costimulation from APCs can compensate for the lack of a CAR-encoded CD28 domain. Thus, Tregs expressing a CAR with or without CD28 are functionally equivalent in vivo, mediating similar extension of skin allograft survival and controlling the generation of anti-HLA-A2 alloantibodies. This study reveals a dimension of CAR-Treg biology and has important implications for the design of CARs for clinical use in Tregs.

摘要

表达嵌合抗原受体 (CAR) 的调节性 T 细胞 (Treg) 是促进移植耐受的有前途的工具。研究了异种免疫缺陷小鼠中 CAR 结构与 Treg 功能之间的关系,揭示了编码 CD28 的 CAR 的优势。然而,这些模型可能无法充分代表 CAR-Treg、抗原呈递细胞 (APC) 和供体特异性 Abs 之间的相互作用。我们生成了表达具有不同共刺激结构域的 HLA-A2 特异性 CAR 的 Treg,并使用同种异体移植的免疫活性模型比较了它们在体外和体内的功能。在体外,编码 CD28 的 CAR 具有优越的抗原特异性抑制、增殖和细胞因子产生。相比之下,在体内,表达编码 CD28、ICOS、程序性细胞死亡 1 和 GITR 的 CAR,但不表达 4-1BB 或 OX40 的 Treg,均可延长皮肤同种异体移植物的存活时间。为了协调体外和体内数据,我们分析了编码 CD3ζ 但没有共刺激结构域的 CAR 的作用。这些数据表明,来自 APC 的外源性共刺激可以弥补 CAR 编码的 CD28 结构域的缺乏。因此,表达具有或不具有 CD28 的 CAR 的 Treg 在体内具有相同的功能,介导类似的皮肤同种异体移植物存活时间延长,并控制抗 HLA-A2 同种抗体的产生。这项研究揭示了 CAR-Treg 生物学的一个维度,对 CAR 在 Treg 中的临床应用设计具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/05b8fdad97b4/jciinsight-8-167215-g148.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/71b3dc838f2c/jciinsight-8-167215-g143.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/b089af7e87a4/jciinsight-8-167215-g144.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/a3c2cc14d8cc/jciinsight-8-167215-g145.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/56e811fc5c4b/jciinsight-8-167215-g146.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/7465cb64cff0/jciinsight-8-167215-g147.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/05b8fdad97b4/jciinsight-8-167215-g148.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/71b3dc838f2c/jciinsight-8-167215-g143.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/b089af7e87a4/jciinsight-8-167215-g144.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/a3c2cc14d8cc/jciinsight-8-167215-g145.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/56e811fc5c4b/jciinsight-8-167215-g146.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/7465cb64cff0/jciinsight-8-167215-g147.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d891/10619441/05b8fdad97b4/jciinsight-8-167215-g148.jpg

相似文献

1
Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection.调节性 T 细胞整合天然和 CAR 介导的共刺激信号,以控制移植物排斥反应。
JCI Insight. 2023 Oct 9;8(19):e167215. doi: 10.1172/jci.insight.167215.
2
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.嵌合抗原受体共刺激结构域调节人调节性 T 细胞功能。
JCI Insight. 2019 Mar 14;5(8):126194. doi: 10.1172/jci.insight.126194.
3
CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.CD8+CD122+PD-1+Tregs 与 CD40/CD154 的共刺激阻断协同作用,但与 B7/CD28 共刺激阻断协同作用,可延长小鼠同种异体移植物的存活时间。
Front Immunol. 2019 Feb 26;10:306. doi: 10.3389/fimmu.2019.00306. eCollection 2019.
4
Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.针对供体HLA I类的嵌合抗原受体的表达增强了人类调节性T细胞预防人类皮肤移植排斥反应的能力。
Am J Transplant. 2017 Apr;17(4):931-943. doi: 10.1111/ajt.14185. Epub 2017 Feb 1.
5
Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.系统性检测和同种异体抗原特异性嵌合抗原受体在调节性 T 细胞中的特异性作图。
JCI Insight. 2019 Mar 21;4(6). doi: 10.1172/jci.insight.123672.
6
Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells.嵌合抗原受体共受体信号结构域在人调节性 T 细胞中的功能效应。
Sci Transl Med. 2020 Aug 19;12(557). doi: 10.1126/scitranslmed.aaz3866.
7
Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients.供体特异性嵌合抗原受体调节性T细胞可限制初次移植而非致敏移植受者的移植排斥反应。
Am J Transplant. 2020 Jun;20(6):1562-1573. doi: 10.1111/ajt.15787. Epub 2020 Feb 11.
8
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.调节性 T 细胞中抗 HLA-A2 嵌合抗原受体的精确工程化用于移植免疫耐受。
Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021.
9
Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival.抗 HLA-A2-CAR Tregs 延长血管化小鼠异位心脏移植的存活时间。
Am J Transplant. 2022 Sep;22(9):2237-2245. doi: 10.1111/ajt.17063. Epub 2022 Apr 27.
10
4-1BB enhancement of CAR T function requires NF-κB and TRAFs.4-1BB 增强 CAR T 功能需要 NF-κB 和 TRAFs。
JCI Insight. 2018 Sep 20;3(18). doi: 10.1172/jci.insight.121322.

引用本文的文献

1
Revolutionizing Allogeneic Graft Tolerance Through Chimeric Antigen Receptor-T Regulatory Cells.通过嵌合抗原受体调节性T细胞革新异基因移植物耐受性
Biomedicines. 2025 Jul 18;13(7):1757. doi: 10.3390/biomedicines13071757.
2
Chronic Graft-versus-host Disease, Part 1: How Preclinical Models Shape Our Understanding of Biology and Pave the Way for Future Therapeutic Interventions.慢性移植物抗宿主病,第1部分:临床前模型如何塑造我们对生物学的理解并为未来的治疗干预铺平道路。
Transplantation. 2025 Jun 24. doi: 10.1097/TP.0000000000005444.
3
CAR Treg synergy with anti-CD154 promotes infectious tolerance and dictates allogeneic heart transplant acceptance.

本文引用的文献

1
Treg suppression of immunity within inflamed allogeneic grafts.调节性 T 细胞抑制炎症性同种异体移植物中的免疫。
JCI Insight. 2022 Aug 22;7(16):e160579. doi: 10.1172/jci.insight.160579.
2
The Dendritic Cell Dilemma in the Skin: Between Tolerance and Immunity.皮肤中的树突状细胞困境:在耐受与免疫之间。
Front Immunol. 2022 Jun 28;13:929000. doi: 10.3389/fimmu.2022.929000. eCollection 2022.
3
Study Design: Human Leukocyte Antigen Class I Molecule A02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation.研究设计:肾移植中人类白细胞抗原I类分子A02嵌合抗原受体调节性T细胞
嵌合抗原受体调节性T细胞(CAR Treg)与抗CD154协同作用可促进感染性耐受并决定异体心脏移植的接受情况。
JCI Insight. 2025 Apr 8;10(7):e188624. doi: 10.1172/jci.insight.188624.
4
Tonic signaling in CAR-T therapy: the lever long enough to move the planet.嵌合抗原受体T细胞(CAR-T)疗法中的张力信号传导:撬动地球的足够长杠杆。
Front Med. 2025 Mar 21. doi: 10.1007/s11684-025-1130-x.
5
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive T cell transfer.对CD3ε进行基因编辑,以重定向调节性T细胞用于过继性T细胞转移。
Mol Ther. 2025 Mar 5;33(3):997-1013. doi: 10.1016/j.ymthe.2025.01.045. Epub 2025 Feb 3.
6
Harnessing the biology of regulatory T cells to treat disease.利用调节性T细胞的生物学特性治疗疾病。
Nat Rev Drug Discov. 2025 Feb;24(2):93-111. doi: 10.1038/s41573-024-01089-x. Epub 2024 Dec 16.
7
Chimeric antigen receptor T-cell therapy in autoimmune diseases.嵌合抗原受体T细胞疗法在自身免疫性疾病中的应用
Front Immunol. 2024 Nov 19;15:1492552. doi: 10.3389/fimmu.2024.1492552. eCollection 2024.
8
Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells.嵌合抗原受体调节性 T 细胞的组合遗传工程策略,用于干细胞衍生的β细胞的免疫保护。
Cell Rep. 2024 Nov 26;43(11):114994. doi: 10.1016/j.celrep.2024.114994. Epub 2024 Nov 18.
9
Chimeric antigen receptor T cell therapy for autoimmune disease.嵌合抗原受体T细胞疗法治疗自身免疫性疾病。
Nat Rev Immunol. 2024 Nov;24(11):830-845. doi: 10.1038/s41577-024-01035-3. Epub 2024 Jun 3.
10
Short Report: CAR Tregs mediate linked suppression and infectious tolerance in islet transplantation.简短报告:嵌合抗原受体调节性T细胞在胰岛移植中介导连锁抑制和感染性耐受。
bioRxiv. 2024 Apr 10:2024.04.06.588414. doi: 10.1101/2024.04.06.588414.
Kidney Int Rep. 2022 Apr 6;7(6):1258-1267. doi: 10.1016/j.ekir.2022.03.030. eCollection 2022 Jun.
4
Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival.抗 HLA-A2-CAR Tregs 延长血管化小鼠异位心脏移植的存活时间。
Am J Transplant. 2022 Sep;22(9):2237-2245. doi: 10.1111/ajt.17063. Epub 2022 Apr 27.
5
Emerging strategies for treating autoimmune disorders with genetically modified Treg cells.利用基因修饰的 Treg 细胞治疗自身免疫性疾病的新兴策略。
J Allergy Clin Immunol. 2022 Jan;149(1):1-11. doi: 10.1016/j.jaci.2021.11.007.
6
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).流式细胞术和细胞分选在免疫学研究中的应用指南(第三版)。
Eur J Immunol. 2021 Dec;51(12):2708-3145. doi: 10.1002/eji.202170126. Epub 2021 Dec 7.
7
Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.瞬时 mTOR 抑制可挽救 4-1BB CAR-Tregs 免受持续信号诱导的功能障碍。
Nat Commun. 2021 Nov 8;12(1):6446. doi: 10.1038/s41467-021-26844-1.
8
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.调节性 T 细胞表达的 CTLA-4 通过 trogocytosis 耗竭 CD80/CD86,使抗原呈递细胞释放游离的 PD-L1。
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30). doi: 10.1073/pnas.2023739118.
9
Navigating CAR-T cells through the solid-tumour microenvironment.CAR-T 细胞在实体瘤微环境中的行进。
Nat Rev Drug Discov. 2021 Jul;20(7):531-550. doi: 10.1038/s41573-021-00189-2. Epub 2021 May 10.
10
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.CD28-跨膜结构域介导嵌合抗原受体与 CD28 的异二聚化。
Front Immunol. 2021 Mar 23;12:639818. doi: 10.3389/fimmu.2021.639818. eCollection 2021.